Norspan (Buprenorphine)

Buprenorphine, the active ingredient in Norspan, is an opioid analgesic presented as a transdermal patch for transdermal use. It treats chronic severe pain, cancer pain and non‑cancer chronic pain in adult patients.

GNH USA supplies Norspan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑origin patches in multiple release rates for global distribution.

Buprenorphine, a partial mu‑opioid receptor agonist, is indicated for several types of chronic pain.

- Chronic severe pain: provides continuous analgesia for patients with persistent severe pain not adequately controlled by other opioids. - Cancer pain: offers sustained pain relief for patients with malignant disease experiencing moderate to severe pain. - Non‑cancer chronic pain: reduces pain intensity in conditions such as osteoarthritis or neuropathic pain when other treatments are insufficient.

Transdermal buprenorphine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Application site erythema: redness or irritation at the patch site. - Pruritus: itching around the patch area. - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, especially with other depressants. - Hypotension: unusually low blood pressure. - Seizures: rare occurrence of convulsive episodes.

When prescribing Norspan, several safety considerations should be observed.

- Patient selection: assess opioid tolerance and history of substance misuse before initiating therapy. - Concomitant CNS depressants: avoid or closely monitor use with benzodiazepines, alcohol, or other sedatives. - Respiratory function: monitor for signs of respiratory depression, particularly during dose escalation. - Skin integrity: inspect the application site regularly for irritation or allergic reaction. - Cardiovascular risk: use caution in patients with severe cardiac disease or hypotension. - Store at room temperature: keep patches below 25 °C in the original pouch, protect from moisture and direct sunlight.

Buprenorphine may interact with other medicines, altering its effect or increasing risk of adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inducers: drugs such as rifampicin can markedly reduce buprenorphine plasma levels. - Combined opioid agonists: using full opioid agonists can increase risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Benzodiazepines: concurrent use may enhance sedation and respiratory depression. - Antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome. - CNS depressants: alcohol or antihistamines may potentiate sedative effects.